Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Dianne Pulte

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Blood|October 6, 2016
Case series of octogenarians with sickle cell diseaseSamir K Ballas, E Dianne Pulte, Clarisse Lobo, et al.
Hemoglobin|November 19, 2014
Erythropoietin levels in patients with sickle cell disease do not correlate with known inducers of erythropoietinE Dianne Pulte, Steven E McKenzie, Jaime Caro, et al.
Blood Advances|January 25, 2018
Survival of ethnic and racial minority patients with multiple myeloma treated with newer medicationsE Dianne Pulte, Lei Nie, Nicole Gormley, et al.
Investigational New Drugs|July 3, 2010
A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancerMargarette Bryan, E Dianne Pulte, Kathleen C Toomey, et al.
The Oncologist|April 26, 2019
U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular RemissionE Dianne Pulte, Tanya Wroblewski, Erik Bloomquist, et al.
The Oncologist|July 19, 2018
FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic LeukemiaE Dianne Pulte, Jonathon Vallejo, Donna Przepiorka, et al.
Thrombosis Research|June 9, 2007
CD39/NTPDase-1 activity and expression in normal leukocytesE Dianne Pulte, M Johan Broekman, Kim E Olson, et al.
Blood|May 10, 2024
Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemiaRobert Q Le, Donna Przepiorka, Haiyan Chen, et al.
Thrombosis Research|June 7, 2005
The ratio of ADP- to ATP-ectonucleotidase activity is reduced in patients with coronary artery diseaseMagdi M El-Omar, Naziba Islam, M Johan Broekman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a <i>FLT3</i> MutationE Dianne Pulte, Kelly J Norsworthy, Yaping Wang, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Blood|October 6, 2016
Case series of octogenarians with sickle cell diseaseSamir K Ballas, E Dianne Pulte, Clarisse Lobo, et al.
Hemoglobin|November 19, 2014
Erythropoietin levels in patients with sickle cell disease do not correlate with known inducers of erythropoietinE Dianne Pulte, Steven E McKenzie, Jaime Caro, et al.
Blood Advances|January 25, 2018
Survival of ethnic and racial minority patients with multiple myeloma treated with newer medicationsE Dianne Pulte, Lei Nie, Nicole Gormley, et al.
Investigational New Drugs|July 3, 2010
A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancerMargarette Bryan, E Dianne Pulte, Kathleen C Toomey, et al.
The Oncologist|April 26, 2019
U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular RemissionE Dianne Pulte, Tanya Wroblewski, Erik Bloomquist, et al.
The Oncologist|July 19, 2018
FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic LeukemiaE Dianne Pulte, Jonathon Vallejo, Donna Przepiorka, et al.
Thrombosis Research|June 9, 2007
CD39/NTPDase-1 activity and expression in normal leukocytesE Dianne Pulte, M Johan Broekman, Kim E Olson, et al.
Blood|May 10, 2024
Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemiaRobert Q Le, Donna Przepiorka, Haiyan Chen, et al.
Thrombosis Research|June 7, 2005
The ratio of ADP- to ATP-ectonucleotidase activity is reduced in patients with coronary artery diseaseMagdi M El-Omar, Naziba Islam, M Johan Broekman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a <i>FLT3</i> MutationE Dianne Pulte, Kelly J Norsworthy, Yaping Wang, et al.
Pageof 2